Is MRNA or MGX more profitable?

Moderna has a net margin of -143.55% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -26.64% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Metagenomi -384.61% -51.23% -36.62%

Which has higher valuation & earnings, IPHA or MGX?

Innate Pharma has higher earnings, but lower revenue than Metagenomi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 17.42 -$55.64M N/A N/A Metagenomi $25.21M 1.85 -$87.87M -$2.30 N/A

Which has preferable valuation and earnings, MGX or ADAG?

Adagene has lower revenue, but higher earnings than Metagenomi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Metagenomi $25.21M 1.85 -$87.87M -$2.30 N/A Adagene $7.67M 24.59 -$17.61M N/A N/A

Is MGX or ADAG more profitable?

Adagene has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Adagene's return on equity of 0.00% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets Metagenomi -384.61% -51.23% -36.62% Adagene N/A N/A N/A

Metagenomi (MGX) Competitors

$1.24 +0.05 (+4.20%)

As of 04:00 PM Eastern

Compare

MGX vs. MRNA, IPHA, ADAG, GALT, and ABOS

Should you buy Metagenomi stock or one of its competitors? MarketBeat compares Metagenomi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Metagenomi include Moderna (MRNA), Innate Pharma (IPHA), Adagene (ADAG), Galectin Therapeutics (GALT), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry.

How does Metagenomi compare to Moderna?

Moderna (NASDAQ:MRNA) and Metagenomi (NASDAQ:MGX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Moderna presently has a consensus price target of $36.60, suggesting a potential downside of 40.00%. Metagenomi has a consensus price target of $9.00, suggesting a potential upside of 625.81%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Moderna had 43 more articles in the media than Metagenomi. MarketBeat recorded 43 mentions for Moderna and 0 mentions for Metagenomi. Moderna's average media sentiment score of 0.40 beat Metagenomi's score of 0.00 indicating that Moderna is being referred to more favorably in the media.

Company	Overall Sentiment
Moderna	Neutral
Metagenomi	Neutral

Moderna has a net margin of -143.55% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -26.64% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Metagenomi	-384.61%	-51.23%	-36.62%

Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

Metagenomi has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	12.45	-$2.82B	-$8.15	N/A
Metagenomi	$25.21M	1.85	-$87.87M	-$2.30	N/A

75.3% of Moderna shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 12.5% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Moderna beats Metagenomi on 9 of the 17 factors compared between the two stocks.

How does Metagenomi compare to Innate Pharma?

Innate Pharma (NASDAQ:IPHA) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Innate Pharma currently has a consensus target price of $5.00, indicating a potential upside of 164.55%. Metagenomi has a consensus target price of $9.00, indicating a potential upside of 625.81%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

0.2% of Innate Pharma shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 12.5% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Innate Pharma's average media sentiment score of 0.00 equaled Metagenomi'saverage media sentiment score.

Company	Overall Sentiment
Innate Pharma	Neutral
Metagenomi	Neutral

Innate Pharma has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Innate Pharma's return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Metagenomi	-384.61%	-51.23%	-36.62%

Innate Pharma has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

Innate Pharma has higher earnings, but lower revenue than Metagenomi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	17.42	-$55.64M	N/A	N/A
Metagenomi	$25.21M	1.85	-$87.87M	-$2.30	N/A

Summary

Innate Pharma beats Metagenomi on 7 of the 12 factors compared between the two stocks.

How does Metagenomi compare to Adagene?

Metagenomi (NASDAQ:MGX) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Adagene has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Adagene's return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Adagene	N/A	N/A	N/A

Metagenomi currently has a consensus target price of $9.00, indicating a potential upside of 625.81%. Adagene has a consensus target price of $8.00, indicating a potential upside of 101.01%. Given Metagenomi's higher possible upside, analysts plainly believe Metagenomi is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Adagene has lower revenue, but higher earnings than Metagenomi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.85	-$87.87M	-$2.30	N/A
Adagene	$7.67M	24.59	-$17.61M	N/A	N/A

9.5% of Adagene shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Metagenomi has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Adagene has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

In the previous week, Adagene had 1 more articles in the media than Metagenomi. MarketBeat recorded 1 mentions for Adagene and 0 mentions for Metagenomi. Adagene's average media sentiment score of 0.36 beat Metagenomi's score of 0.00 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
Metagenomi	Neutral
Adagene	Neutral

Summary

Adagene beats Metagenomi on 11 of the 15 factors compared between the two stocks.

How does Metagenomi compare to Galectin Therapeutics?

Metagenomi (NASDAQ:MGX) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

11.7% of Galectin Therapeutics shares are held by institutional investors. 12.5% of Metagenomi shares are held by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Galectin Therapeutics had 4 more articles in the media than Metagenomi. MarketBeat recorded 4 mentions for Galectin Therapeutics and 0 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.00 equaled Galectin Therapeutics'average media sentiment score.

Company	Overall Sentiment
Metagenomi	Neutral
Galectin Therapeutics	Neutral

Galectin Therapeutics has lower revenue, but higher earnings than Metagenomi. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.85	-$87.87M	-$2.30	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

Metagenomi has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

Metagenomi currently has a consensus price target of $9.00, indicating a potential upside of 625.81%. Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 252.56%. Given Metagenomi's stronger consensus rating and higher possible upside, equities analysts plainly believe Metagenomi is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Galectin Therapeutics' return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Galectin Therapeutics	N/A	N/A	-164.69%

Summary

Metagenomi beats Galectin Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Metagenomi compare to Acumen Pharmaceuticals?

Metagenomi (NASDAQ:MGX) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Metagenomi has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

In the previous week, Acumen Pharmaceuticals had 5 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for Acumen Pharmaceuticals and 0 mentions for Metagenomi. Acumen Pharmaceuticals' average media sentiment score of 0.12 beat Metagenomi's score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Metagenomi	Neutral
Acumen Pharmaceuticals	Neutral

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 12.5% of Metagenomi shares are held by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Metagenomi presently has a consensus target price of $9.00, suggesting a potential upside of 625.81%. Acumen Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 231.95%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Metagenomi has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.85	-$87.87M	-$2.30	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Acumen Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Summary

Metagenomi beats Acumen Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Metagenomi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGX vs. The Competition

Export

Metric	Metagenomi	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$44.80M	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-0.54	18.43	24.92	23.97
Price / Sales	1.85	336.82	528.81	109.59
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	0.29	4.11	10.79	6.50
Net Income	-$87.87M	$64.45M	$3.56B	$336.88M
7 Day Performance	8.77%	2.24%	1.67%	-0.22%
1 Month Performance	-8.15%	1.04%	0.43%	0.77%
1 Year Performance	-12.68%	30.05%	32.84%	31.57%

Metagenomi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGX Metagenomi	2.5397 of 5 stars	$1.24 +4.2%	$9.00 +625.8%	-17.9%	$44.80M	$25.21M	N/A	236	Gap Down
MRNA Moderna	1.2411 of 5 stars	$53.37 +2.4%	$36.60 -31.4%	+129.2%	$21.28B	$1.94B	N/A	4,700
IPHA Innate Pharma	2.4186 of 5 stars	$1.80 +0.8%	$5.00 +177.2%	+0.6%	$169.43M	$10.19M	N/A	220	Gap Up
ADAG Adagene	2.5132 of 5 stars	$3.59 -1.4%	$8.00 +122.9%	+102.1%	$169.42M	$7.67M	N/A	260	News Coverage Gap Down
GALT Galectin Therapeutics	1.4387 of 5 stars	$2.57 -1.9%	$11.00 +328.0%	+15.7%	$169.26M	N/A	N/A	9	News Coverage Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Metagenomi (MGX) Competitors

MGX vs. MRNA, IPHA, ADAG, GALT, and ABOS

How does Metagenomi compare to Moderna?

Summary

How does Metagenomi compare to Innate Pharma?

Summary

How does Metagenomi compare to Adagene?

Summary

How does Metagenomi compare to Galectin Therapeutics?

Summary

How does Metagenomi compare to Acumen Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Metagenomi (MGX) Competitors

MGX vs. MRNA, IPHA, ADAG, GALT, and ABOS

How does Metagenomi compare to Moderna?

Do analysts rate MRNA or MGX?

Does the media prefer MRNA or MGX?

Is MRNA or MGX more profitable?

Which has more volatility & risk, MRNA or MGX?

Which has better valuation & earnings, MRNA or MGX?

Do institutionals and insiders hold more shares of MRNA or MGX?

Summary

How does Metagenomi compare to Innate Pharma?

Do analysts rate IPHA or MGX?

Do insiders & institutionals have more ownership in IPHA or MGX?

Does the media prefer IPHA or MGX?

Is IPHA or MGX more profitable?

Which has more volatility and risk, IPHA or MGX?

Which has higher valuation & earnings, IPHA or MGX?

Summary

How does Metagenomi compare to Adagene?

Is MGX or ADAG more profitable?

Do analysts prefer MGX or ADAG?

Which has preferable valuation and earnings, MGX or ADAG?

Do insiders & institutionals have more ownership in MGX or ADAG?

Which has more volatility & risk, MGX or ADAG?

Does the media refer more to MGX or ADAG?

Summary

How does Metagenomi compare to Galectin Therapeutics?

Do institutionals and insiders have more ownership in MGX or GALT?

Does the media refer more to MGX or GALT?

Which has better earnings & valuation, MGX or GALT?

Which has more volatility and risk, MGX or GALT?

Do analysts recommend MGX or GALT?

Is MGX or GALT more profitable?

Summary

How does Metagenomi compare to Acumen Pharmaceuticals?

Which has more risk and volatility, MGX or ABOS?

Does the media favor MGX or ABOS?

Do insiders & institutionals have more ownership in MGX or ABOS?

Do analysts recommend MGX or ABOS?

Which has higher earnings and valuation, MGX or ABOS?

Is MGX or ABOS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools